GIA632 + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-segmental Vitiligo
Conditions
Non-segmental Vitiligo
Trial Timeline
Mar 9, 2026 → Feb 14, 2030
NCT ID
NCT07431177About GIA632 + Placebo
GIA632 + Placebo is a phase 2 stage product being developed by Novartis for Non-segmental Vitiligo. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07431177. Target conditions include Non-segmental Vitiligo.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07431177 | Phase 2 | Recruiting |
Competing Products
8 competing products in Non-segmental Vitiligo
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR0302 Tablets + SHR0302 Base Gel + SHR0302 Placebo Tablets + SHR0302 Base Placebo Gel | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 52 |
| MK-6194 + Placebo | Merck | Phase 2 | 52 |
| PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + placebo + PF06700841 | Pfizer | Phase 2 | 51 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Roflumilast topical 0.3% foam | Arcutis Biotherapeutics | Phase 2 | 47 |
| VYN201 Gel + Vehicle Gel | Vyne Therapeutics | Phase 2 | 44 |